A best-in-class global molecular diagnostic platform to democratize point of care and home use testing, thus contributing to the prevention of infectious disease transmission and better health for the citizens of the world.
Contribute to the early detection and prevention of infectious disease transmission
Leverage our proprietary AntiSense molecular RNA diagnostic platform across multiple infectious disease diagnostic categories
Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic test kits that will democratize testing for use at point of care and in home
The Company’s first products are AntiSense molecular diagnostic test kits that accurately, quickly and affordably detect respiratory infections, including Covid-19 in less than 5 minutes
Our AntiSense molecular diagnostic test delivers the gold standard testing accuracy of a RT-PCR test, with the speed of the fastest rapid tests
The AntiSense molecular diagnostic platform will be further expanded for use in testing for other infectious diseases
1 billion Covid-19 molecular tests administered globally in 2020
Click here for link to Health Canada Covid-19 Infobase
Click here for link to US Government CDC Covid-19 Tracker Data
Click here for link to University of Oxford – Our World in Data Global Database
RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care (“POC”) and home-use infectious disease detection, announced today the appointments of its Chief Scientific Advisor, Professor Dipanjan Pan, M.S., Ph.D., and its President, John W. Erickson, Jr., to the Company’s Board of Directors.
Read MoreRNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today that it has secured an exclusive global license to a rapid ribonucleic acid (“RNA”)-based molecular Lateral Flow Assay (“LFA”) technology jointly owned by the University of Maryland, Baltimore (“UMB”) and the University of Maryland, Baltimore County (“UMBC”).
Read More
We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.
LEARN MORE
1114 Avenue of the Americas, 23rd Floor, New York, New York 10036.7703
79 Wellington St W #3300, Toronto, Ontario, M5K 1N2